NLA Nasal Spray - Meda

Drug Profile

NLA Nasal Spray - Meda

Alternative Names: NCX-1510; Nitric oxide-releasing cetirizine liposomal - Orexo; NLA; NO-releasing cetirizine liposomal - Orexo; OX-NLA

Latest Information Update: 03 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Developer Meda
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 09 Mar 2012 Clinical development is ongoing in Sweden
  • 14 Apr 2008 Orexo's cetirizine-based nasal spray licensed worldwide to Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top